Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study

BACKGROUND: Lopinavir/ritonavir (LPV/r) is a drug traditionally used for the treatment of HIV that has been repurposed as a potential post-exposure prophylaxis agent against COVID-19 in the COronavirus Post-Exposure Prophylaxis (COPEP) study. The present analysis aims to evaluate LPV levels in indiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Thoueille, Paul, Delfraysse, Margot, Andre, Pascal, Buclin, Thierry, Decosterd, Laurent A., Fedeli, Chiara, Ustero, Pilar, Calmy, Alexandra, Guidi, Monia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536696/
https://www.ncbi.nlm.nih.gov/pubmed/37759315
http://dx.doi.org/10.1186/s40360-023-00687-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536696/
https://www.ncbi.nlm.nih.gov/pubmed/37759315
http://dx.doi.org/10.1186/s40360-023-00687-6

Ejemplares similares